J&J, Bayer seeking stent thrombosis reduction with Xarelto
This article was originally published in Scrip
Executive Summary
Johnson & Johnson subsidiary Janssen Research & Development has been on a roll with submitting applications to the US FDA for the firm's oral anticoagulant Xarelto (rivaroxaban) – just last week putting in the paperwork to market the drug as a treatment for patients with deep vein thrombosis (DVT) or pulmonary embolism and as a therapy to prevent recurrent venous thromboembolism (VTE) (scripintelligence, 3 May 2012).